Daré Bioscience Stock Is Trading Higher As Bacterial Vaginosis Candidate Secures FDA Priority Review

by Vandana Singh, Benzinga Editor

August 9, 2021 11:21 AM | 1 min read |

The FDA has accepted for review Daré Bioscience Inc's DARE marketing application for DARE-BV1 for bacterial vaginosis.
Under the priority review, the target goal date is December 7.
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time treatment.
The application is supported by positive data from the DARE-BVFREE Phase 3 study, demonstrating 70-81% clinical cure rates from a single vaginal dose of DARE-BV1.
Price Action: DARE shares are up 7.45% at $1.73 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech Long Ideas News Penny Stocks Health Care FDA Movers Trading Ideas General Briefs FDA Priority Review

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.